Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Nutrition and ExerciseNutrition and Exercise
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


ibalizumab
May 19, 2014

Dear Nelson, I appreciate you so much for your effort in defending HIV and tell us more information about Ibalizumab . On April 24 you talked about Ibalizumab and you wrote that we hopefully will hear something by June.Do you have any new good news about it now?

Response from Mr. Vergel

We are still waiting about the FDA review of the drug for orphan drug status. It may happen soon, I hope.

Orphan drug status will make it easier for the IV administration to get approved for patients with limited HIV treatment options.

Are you waiting to access ibalizumab?

I am also following two new drugs closely made by BMS. They have an attachment and a maturation inhibitor that will start their phase 3 studies early next year. Both drugs could work in deep salvage patients.

Check back with me in a month or so to keep you updated. What is your current situation?

Nelson



Previous
Testosterone
Next
terapia reemplazo hormonal

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement